Tariff Policy Shifts Stalled Pharmaceutical Investment
North Carolina pharmaceutical firms faced increased market uncertainty throughout 2025 due to volatile trade policies.
Updated on Oct. 14, 2026 in International Trade
Live Poll
Do you worry that trade tariffs will make your future medical treatments harder to afford?
Pharmaceuticals ranked as North Carolina's top trade commodity in 2025, but shifting tariff policies created significant volatility for the state's industry. The instability complicated long-term operational planning for companies managing intensive drug development cycles.
Why it matters
Pharmaceutical firms require predictable regulatory and trade environments to sustain 10 to 15-year development timelines. Constant shifts in international trade status forced investors to redirect capital away from smaller companies, threatening the pipeline of future medical treatments.
Pharmaceuticals held the rank of the number one trade commodity in North Carolina throughout 2025. Development timelines for these products typically span 10 to 15 years, requiring stability that current trade policy fluctuations disrupted.
The players
AbbVie Inc.
A global biopharmaceutical company focused on research and development, which announced a new manufacturing facility in Durham in 2025.
Genentech
A biotechnology corporation and subsidiary of Roche that announced major expansion plans in North Carolina in May 2025.
The details
The pharmaceutical industry relies heavily on stable trade relations with key partners Canada and Mexico to manage supply chains and manufacturing. Tariff volatility hinders consistent decision-making, prompting small firms to seek manufacturing opportunities overseas to mitigate risks. This environment creates a challenging landscape for local expansions, such as those planned by major industry players in the Research Triangle.
Timeline
April 2025: AbbVie Inc. announced plans for a new manufacturing facility in Durham.
May 2025: Genentech announced expansion plans within North Carolina.
2025: Pharmaceuticals became the leading trade commodity in the state.
Market Landscape
The volatility surrounding 2025 trade policies marked a significant departure from the stability fostered by the United States-Canada-Mexico Agreement framework. This friction forces regional hubs like North Carolina to contend with market dynamics that prioritize short-term risk over long-term research.
Operators in the pharmaceutical sector should factor in extended development timelines and potential capital scarcity when modeling long-term facility expansions. Monitoring trade status with primary partners remains critical for maintaining the margins necessary for multi-year R&D projects.
The takeaway
Trade uncertainty creates a direct drag on long-term capital investment for high-cost, long-horizon industries like pharmaceuticals. Operators should prioritize liquidity and maintain flexible manufacturing strategies to adapt to rapid shifts in global trade status.
Further reading
For broader analysis on supply chain risks, visit the International Trade section.
Source note: This article includes information reported by Carolina Journal.
Live Poll
Do you worry that trade tariffs will make your future medical treatments harder to afford?
